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Background: The impact of preoperative diabetic treatment status on cardiovascular outcomes after coronary revascularization has not been fully 
studied. This study aims to evaluate the association between preoperative diabetic treatment status and cardiovascular outcomes in patients with 
type 2 diabetes mellitus (DM) after coronary revascularization.
Methods: During 2000-2002, 9877 patients undergoing first PCI or CABG at 30 hospitals in Japan were enrolled to CREDO-Kyoto registry. This 
study consisted of 9572 patients: 5912 nondiabetic patients (non-DM) and 3660 type 2 DM patients. DM patients were divided into 4 groups: 783 
with insulin therapy (IG), 1659 with oral hypoglycemic agents (OG), 573 with only diet therapy (DG), 645 with no glycemic therapy (NG). Patients with 
malignancy were excluded. 
Results: Average HbA1c values were higher in IG (7.7%) and OG (7.3%) than in DG (6.6%) and NG (6.8%) (p<0.0001). The rate of freedom from 
major adverse cardiovascular events (MACE), a composite of cardiovascular death, myocardial infarction and stroke were as follows: non-DM, IG, OG, 
DG, NG at 3 years; 90.1% (reference), 80.9% (log rank p<0.0001), 87.1% (p=0.002), 87.7% (p=0.07), 84.2% (p<0.0001), respectively. Multivariate 
Cox’s proportional hazard models using non-DM as a reference revealed that IG, OG and NG, but not DG, were significantly associated with increased 
risks of MACE. Multivariate models among DM patients using DG as a reference demonstrated that IG and NG were significantly associated with 
increased risks of MACE (IG: HR 1.39, 95% C.I. 1.05-1.85, p=0.02; OG: HR 1.03, 95% C.I. 0.77-1.40, p=0.82, NG: HR 1.37, 95% C.I. 1.01-1.85, 
p=0.04 ). Other significant predictors of MACE among DM patients included age>75 years, revascularization by PCI, history of heart failure, history of 
stoke, peripheral vascular disease, atrial fibrillation, hemodialysis, chronic kidney disease, left main trunk disease, multivessel disease and no anti-
platelets therapy. 
Conclusions: In type 2 DM patients undergoing first coronary revascularization, those with insulin therapy and those with no glycemic therapy were 
associated with adverse cardiovascular outcomes, irrespective of their HbA1c levels.
